Javier Martinez-Picado is ICREA Research Professor at the IrsiCaixa AIDS Research Institute in Barcelona. He is also an associate professor at the University of Vic, and an elected member of the Royal Academy of Science and Arts of Barcelona. He obtained his PhD in Microbiology from the University of Barcelona, where he also lectured as an associate professor. In 1996, he joined Massachusetts General Hospital as a research fellow at Harvard Medical School, where he focused on HIV/AIDS research. In 2000 he obtained the position of biomedical researcher at the Spanish Health Department appointed to the Hospital Germans Trias de Badalona. In 2006 he obtained his current ICREA position. Dr. Martinez-Picado serves on different government, academic and industry advisory boards. He has given numerous invited lectures in multiple countries, and has published more than 240 articles on virology and immunology topics, mainly related to the pathogenesis of HIV, in international journals.
His research is focused on characterizing the immuno-virological mechanisms of viral pathogenesis in human diseases, including HIV-1, Ebola virus, arenaviruses and, more recently, SARS-CoV-2. His group’s translational program has the ultimate goal of investigating potential new viral therapeutic strategies, especially in the field of HIV/AIDS, through basic and applied research. They work closely with other national and international biomedical institutes, focusing on three priority research topics: understanding viral persistence to tackle HIV cure strategies, viral pathogenesis mediated by myeloid cells, and extreme phenotypes of virus disease progression. As a result of the COVID-19 pandemic, they have expanded their research to the pathogenesis of SARS-CoV-2, implementing organoid models to assess viral infection and inflammatory responses.
- Bastard P et al 2022, 'Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs', Sci Immunol, 7, 74.
- Gunst J et al 2022, 'Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial', Nat Med, 28, 2424–35.
- Moron-Lopez S et al. 2022, 'ABX464 Decreases the Total HIV Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy-Suppressed Individuals Living With HIV' Clin Infect Dis, 74(11), 2044–2049.
- Galvez C et al 2022, 'Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA' J Intern Med, 292(2):308-20.
- Perez-Zsolt D et al, 2022, 'Receptors on primary phagocytes as therapeutic targets against highly pathogenic emerging viruses' T Roy Soc Chem, Chapter 11, 256 - 279.
- Izquierdo-Pujol J et al., 2022, 'Post COVID-19 Condition in Children and Adolescents: An Emerging Problem' Front Pediatr, 10:894204.
- Odeny TA et al 2022, 'Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer' J Immunother Cancer, 10:e005128.
- Manry J et al 2022, 'The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies' PNAS USA, 119(21):e2200413119.
- Borgognone A et al 2022, 'Gut microbiome signatures linked to HIV-1 reservoir size and viremia control' Microbiome 10(1):59.
- Ezeonwumelu IJ et al 2022, 'IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation' Front Immunol, 13:1001068
- Huyveneers L et al. 2022, 'Autopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5Δ32/Δ32 Donor Cells' Viruses, 14(9):2069.
- Zhang Q et al., 2022, 'Human genetic and immunological determinants of critical COVID-19 pneumonia' Nature, 603(7902):587-98.